A phase II trial of gefitinib for recurrent or metastatic cancer of the esophagus or gastroesophageal junction-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A phase II trial of gefitinib for recurrent or metastatic cancer of the esophagus or gastroesophageal junction

Published:2011-08-24 Issue:4 Volume:30 Page:1684-1689
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Adelstein David J.,Rodriguez Cristina P.,Rybicki Lisa A.,Ives Denise I.,Rice Thomas W.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10637-011-9736-z.pdf

Reference35 articles.

1. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60:277–300

2. Enzinger PC, Mayer RJ (2003) Esophageal cancer. N Engl J Med 349:2241–2252

3. Ilson DH, Ajani J, Bhalla K et al (1998) Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. J Clin Oncol 16:1826–1834

4. El-Rayes BF, Shields A, Zalupski M et al (2004) A phase II study of carboplatin and paclitaxel in esophagus cancer. Ann Oncol 15:960–965

5. Ajani JA, Moiseyenko VM, Tjulandin S et al (2007) Clinical benefit with doxetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal adenocarcinoma: the V-325 study group. J Clin Oncol 25:3205–3209

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. EGFR mutations and abnormal trafficking in cancers;Molecular Biology Reports;2024-08-21

2. EGFR and PI3K Signalling Pathways as Promising Targets on Circulating Tumour Cells from Patients with Metastatic Gastric Adenocarcinoma;International Journal of Molecular Sciences;2024-05-20

3. Identification of Molecular Subtypes and Potential Small-Molecule Drugs for Esophagus Cancer Treatment Based on m6A Regulators;Journal of Oncology;2022-01-13

4. Larotinib in patients with advanced and previously treated esophageal squamous cell carcinoma with epidermal growth factor receptor overexpression or amplification: an open-label, multicenter phase 1b study;BMC Gastroenterology;2021-10-23

5. Pan-ERBB kinase inhibition augments CDK4/6 inhibitor efficacy in oesophageal squamous cell carcinoma;Gut;2021-03-31

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3